Recent events
Recent events tied to this brand in public sources.
Back to profile64 entries · Page 2 of 4
2021
FDA approves Astepro for nonprescription sale
The U.S. Food and Drug Administration approved Bayer's Astepro nasal spray for sale without a prescription.
2021
Bayer announces acquisition agreements for Noria and PSMA Therapeutics
Bayer announced that it had entered into acquisition agreements with Noria Therapeutics and PSMA Therapeutics, including rights to an actinium-225-labeled small molecule targeting PSMA for prostate cancer treatment.
2021
LHC Group files complaint against Bayer over Essure
LHC Group filed a complaint against Bayer and others concerning the allegedly defective Essure birth-control device. The plaintiff alleged that Bayer negligently monitored and reported complications and continued marketing the product as safe and effective; these are allegations in the complaint, not a court determination.
2021
GreenLight Biosciences acquires rights to Bayer topical RNA IP
GreenLight Biosciences announced that it had acquired rights to portions of Bayer's topical RNA intellectual property portfolio, including bee-health capabilities intended to protect against Varroa mites.
2021
Bayer launches Beirun skincare brand
Bayer launched the new Beirun skincare brand at the 26th China Beauty Expo, which opened on May 12.
2021
ESSA Pharma and Bayer enter clinical collaboration and supply agreement
ESSA Pharma announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with darolutamide in patients with metastatic castration-resistant prostate cancer. Bayer may sponsor and conduct a Phase 1/2 study; ESSA will supply EPI-7386 and retain all rights to the candidate.
2021
FDA approves Verquvo for adults with symptomatic chronic heart failure
The U.S. Food and Drug Administration approved Merck & Co.'s Verquvo to reduce cardiovascular death and heart failure hospitalization risk in specified adults with symptomatic chronic heart failure.
2020
Bayer and Arogya Finance announce Eylea payment partnership in India
Bayer and Arogya Finance announced a collaboration to introduce the Eylea Easy Pay Program in India, offering patients flexible payment solutions for Eylea treatment.
2020
Bayer wins 2020 Outstanding Contribution to Sustainable Development Award
Bayer won the 2020 Outstanding Contribution to Sustainable Development Award for its Healthy Vision public welfare project. The event was held the previous day, December 9, 2020.
2020
BlockApps launches TraceHarvest Network
BlockApps announced the launch of TraceHarvest, a blockchain-powered agricultural business network developed in collaboration with Bayer. Bayer was a founding member and used the network for customer-facing operations in regions including the United States and Brazil.
2020
Bayer announces Beijing plant capacity expansion
Bayer announced an investment of more than €50 million to expand capacity at its Beijing prescription medicine factory. The completed project is expected to increase annual plant capacity by about 40% and is planned to enter use by the end of 2022.
2020
Bayer announces acquisition of AskBio
Bayer announced that it would acquire Asklepios BioPharmaceutical (AskBio), expanding its cell and gene therapy capabilities.
2020
Bayer asks California Supreme Court to review Roundup verdict
Bayer asked the California Supreme Court to review a decision affirming a $20.5 million award to groundskeeper Dewayne Johnson, who claimed Roundup caused his cancer. Bayer argued the ruling conflicted with federal law and settled legal principles; the request was an appeal, not a new court determination.
2020
Bayer and Recursion enter strategic collaboration on fibrotic diseases
Bayer and Recursion Pharmaceuticals entered a strategic collaboration to use Recursion's AI-guided drug discovery platform and Bayer's compound library and scientific expertise to discover and develop treatments for fibrotic diseases.
2020
Bayer and Hua Medicine form a strategic partnership to develop dorzagliatin
Bayer and Hua Medicine formed a strategic partnership to jointly develop the diabetes drug dorzagliatin. Hua Medicine will handle clinical development, registration, supply and distribution, while Bayer will provide marketing, promotion and medical education services in China.
2020
FDA approves Lampit for pediatric Chagas disease treatment
The U.S. Food and Drug Administration approved Lampit (nifurtimox) for treating Chagas disease in pediatric patients from birth to under 18 years old who weigh at least 2.5 kg. The article says Lampit is not approved in the U.S. for adults aged 18 or older.
2020
California appeals court upholds Monsanto liability in Roundup cancer case
A California appeals court denied Monsanto a new trial and affirmed its liability to Dewayne Johnson, while reducing the damages and conditioning the denial of a new trial on Johnson accepting the reduced amounts. The judges said Johnson presented substantial evidence that Roundup products caused his cancer.
2020
California appeals court upholds Roundup verdict and reduces damages
A California appeals court rejected Bayer’s bid to overturn a verdict for a school groundskeeper who claimed Roundup caused his cancer, while reducing the damages to US$20.5 million. The court said the plaintiff offered abundant evidence that glyphosate together with other ingredients in Roundup products caused his cancer.
2020
California appeals court upholds Monsanto liability and reduces award
The California Court of Appeal in San Francisco upheld the liability verdict against Monsanto in Dewayne Johnson's Roundup case and reduced his award from $78.5 million to $20.5 million. Bayer said it continued to believe the verdict and awards were inconsistent with the trial evidence and law.
2020
Bayer teams up with pharmacy chains to create dermatology health centers
Bayer upgraded its dual-brand strategy and teamed up with pharmacy chains to create dermatology health centers combining health education, medication consultation and purchasing experiences.